Spotlight Session 2
Panel discussion with industry leaders

Recent Trends and Future Prospects in Neuropsychopharmacology from a Pharmaceutical Manufacturer's Perspective

2024年5月24日(金) 13:30 〜 14:30 Room 10 (G402)

Chair: Suresh Sundram (Monash University)

Summary:
Panel discussion session with representatives from three to four pharmaceutical manufacturers. This 60-minute session will consist of two parts: oral presentations by representatives of each company and a panel discussion. In the first half of the session, each representative will speak freely about their latest initiatives and future prospects for approximately 10 minutes (no Q&A). After the oral presentations by each company, a panel discussion will be held with representatives as panelists and a chairperson selected from CINP's EC members. The main points of the panel discussion will be presented in advance.

+全てマイスケジュールに登録

[SS2-1]

*Peter Fang¹ (1. Worldwide Vice President, Global Commercial Strategy Organization, Janssen Pharmaceutical Companies of Johnson & Johnson)

[SS2-2] -

*Vaidrius Navikas¹ (1. Senior Vice President, Head of Global Medical Affairs, H. Lundbeck A/S)

[SS2-3]

*Christoph von der Goltz¹ (1. Head of Medicine Therapeutic Area CNS, Retinopathies and Emerging Markets, Boehringer Ingelheim Pharma GmbH & Co. KG)

[SS2-4]

*Harald Hampel¹ (1. Senior Vice President, Chief Medical Officer, Neurology Medical Affairs Executive, DHBL & Medical Affairs, Global AD Officer, Eisai Inc.)